Aetna
Aetna Aetna
Specialty Pharmacy Clinical Policy Bulletins
Aetna Non-Medicare Prescription Drug Plan
Subject: Specialty Quantity Limit Zeposia 4775-H P2023a

Drug
ZEPOSIA  (ozanimod)


Policy:

I.  PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.


II.  COVERED QUANTITIES

        Medication

         Standard Limit

                     FDA-recommended dosing

  Zeposia (ozanimod)
  7-Day Starter Pack
  (four 0.23 mg capsules
  and three 0.46 mg
  capsules)

  1 Starter Pack
  (7 capsules) per 7 days

 

  Multiple Sclerosis and Ulcerative Colitis
  •   Treatment initiation:
       º   Days 1-4: 0.23 mg daily
       º   Days 5-7: 0.46 mg daily
  •   Maintenance dose: 0.92 mg daily starting on day 8

 

 

  Zeposia (ozanimod)
  (37-day) Starter Kit
  (one 7-Day Starter Pack
  and one bottle of thirty
  0.92 mg capsules)

  1 Starter Kit
  (37 capsules) per 37 days

  Zeposia (ozanimod)
  (28-day) Starter Kit
  (one 7-Day Starter Pack
  and twenty-one 0.92 mg
  capsules)

  1 Starter Kit
  (28 capsules) per 28 days

  Zeposia (ozanimod)
  0.92 mg capsules

  30 capsules per 30 days

 


Place of Service:

Outpatient

The above policy is based on the following references:
  1. Zeposia [package insert]. Princeton, NJ: Bristol-Meyers Squibb Company; August 2023.
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

February 11, 2024
Aetna
Skip Past Footer Links
Company Information   |   Site Map Aetna.com Home   |   Help   |   Contact Us   |   Search
Web Privacy Statement   |   Legal Statement   |   Privacy Notices   |   Member Disclosure

Back to top